Effect of tumor burden and route of administration on the immunotherapeutic properties of polyinosinic-polycytidylic acid stabilized with poly-l-lysine in carboxymethyl cellulose [Poly(I,C)-LC]

Paul L. Black, Diethelm Hartmann, Robin Pennington, Hamblin Phillips, Mark Schneider, Henry R. Tribble, James E Talmadge

Research output: Contribution to journalArticle

10 Scopus citations


We examined the immunomodulatory and therapeutic activities of poly(I,C-LC. Mice received a subcutaneous (s.c.) injection of sufficient numbers of MBL-2 lymphoma cells to produce in 1 week either a high or low tumor burden. A week after tumor cell injection, poly(I,C)-LC treatment was initieated; the agent was administered intraperitoneally (i.p.) at 5 mg/kg twice a week or at 2.5 or 0.5 mg/kg every day or as an intravenous (i.v.) injection at 0.5, 0.05, or 0.005 mg/kg three times a week. Poly(I,C)-LC treatment significantly increased antitumor effector cell functions in a variey of organs (including spleen, lungs, and peritoneum), as shown by increased killing of MBL-2 cells in vitro and increased tumor cell killing by natural killer cells and macrophages. Furthermore, prolongation of survival correlated with peritoneal macrophage tumoricidal activity when poly(I,C)-LC was given i.p. and with pulmonary effector cell function (including natural killer, cytolytic T-lymphocyte and macrophage tumoricidal activity) when the agent was administered i.v.

Original languageEnglish (US)
Pages (from-to)1341-1353
Number of pages13
JournalInternational Journal of Immunopharmacology
Issue number8
Publication statusPublished - Nov 1992


ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this